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We investigated chloroquine sensitivity to Plasmodium 
falciparum in travelers returning to France and Canada from 
Haiti during a 23-year period. Two of 19 isolates obtained 
after the 2010 earthquake showed mixed pfcrt 76K+T 
genotype and high 50% inhibitory concentration. Physicians 
treating malaria acquired in Haiti should be aware of 
possible chloroquine resistance.
In Haiti (2011 population ≈9.7 million), malaria is endemic. Approximately 30,000 malaria infections are 
confi rmed annually among ≈200,000 estimated malaria 
cases, mainly Plasmodium falciparum infections (1). 
On January 12, 2010, a 7.0 magnitude earthquake struck 
Haiti near Port-au-Prince, leaving much of the population 
homeless.
The main malaria vector in Haiti, Anopheles albimanus 
mosquitoes, which mostly bite outdoors during November–
January, placed evacuees at high risk for infection (2,3). 
Severe fl ooding after hurricane Tomas in November 2010 
probably compounded the problem by facilitating parasite 
reservoirs and mosquito breeding (4). Some studies suggest 
that these events might have increased malaria transmission 
in Haiti. Two observational surveys, 1 performed by a 
mobile medical team during March–April 2010 (5) and 1 
during November 2010–February 2011 in a primary care 
clinic in Leogane (6), reported a high proportion of malaria 
infection among persons with fever (20.3% and 46.9%, 
respectively) compared with reports from a population-
based survey in 2006 (14.2%) (2). The US National Malaria 
Surveillance System reported a 3-fold increase in malaria 
among travelers returning from Haiti in 2010 (170 cases) 
compared with 2009 (58 cases) (7).
Chloroquine associated with primaquine since 2009, 
is the recommended fi rst-line treatment for uncomplicated 
malaria. In vitro and molecular surveillance data collected 
during the past 2 decades suggest continued P. falciparum 
sensitivity to chloroquine (3,8,9). However, a 2006–2007 
study in Artibonite Valley, Haiti, showed the chloroquine 
resistance–associated Pfcrt76T genotype in ≈6% (5/79) 
of P. falciparum isolates, although clinical data were 
lacking (10). Subsequently, the Haitian Ministry of 
Health acknowledged that routine chloroquine effi cacy 
surveillance should be reinforced (11). We investigated the 
chloroquine sensitivity of P. falciparum parasites isolated 
from travelers recently returned from Haiti to Canada and 
France by using genotypic and phenotypic methods.
The Study
We collected retrospective data from the National 
Malaria Reference Centre (Paris, France) and Public 
Health Ontario (Toronto, ON, Canada) during 1988–2010 
and 2007–2010, respectively. P. falciparum infection 
was considered probably acquired in Haiti if biologically 
confi rmed by thin and thick blood smears from persons 
who had recently traveled to Haiti in the 2 months 
before infection was diagnosed. Basic demographic and 
epidemiologic data, clinical and parasitologic information, 
treatment, and history of travel and P. falciparum infection 
were collected systematically. Forty of 80 participating 
hospitals in the sentinel network in France also documented 
resistance to antimalarial drugs. Pretreatment isolates 
were collected to determine chloroquine susceptibility by 
molecular analysis of the Pfcrt76 locus and by comparing 
the ratio of in vitro chloroquine response of the clinical 
isolate with a chloroquine-sensitive reference clone.
Seventy-nine imported P. falciparum infections were 
recorded: 49 before the earthquake (all in France) and 30 
after the earthquake (3 in Canada and 27 in France). The 
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number of confi rmed malaria cases imported from Haiti 
doubled during 2009–2010 (Figure 1). Approximately 
half of the travelers were in Haiti 2–4 weeks before the 
earthquake and >1 month after the earthquake. The main 
purpose of travel, visiting friends and relatives, decreased 
from 59% before to 44% after the earthquake. More than 
75% of travelers did not take prophylactic medication. The 
proportion of severe malaria increased from 3% to 11% 
after January 2010 (Table 1).
Before the earthquake, all 29 isolates had the wild-type 
PfcrtK76 allele according to analysis by PCR–restriction 
fragment-length polymorphism. The mean 50% inhibitory 
concentration (IC50) of chloroquine for the 24 isolates 
tested ex vivo by the 3H-hypoxanthine uptake inhibition 
method was 27 nM (95% CI 23–31). These results are 
consistent with those of an unpublished study conducted in 
Haiti during 2007 to monitor chloroquine resistance (Jean-
François Vely, unpub. data). In that study, Haiti’s National 
Malaria Program, in collaboration with the National 
Malaria Reference Centre in France, found the chloroquine-
sensitive genotype in 146 P. falciparum–positive samples 
in 6 departments (Artibonite, Centre, Grand’Anse, Nord, 
Nord-Ouest, Ouest) (Figure 2) (12). After the earthquake, 
2 (11%) of 19 isolates analyzed by pyrosequencing 
and PCR–restriction fragment-length polymorphism 
showed a mixed Pfcrt76K+T genotype. The ratios of K 
to T genotypes before and after in vitro adaptation were 
0.75:0.25 and 0.23:0.77, respectively, for patient 1, and 
0.58:0.42 and 0.25:0.75, respectively, for patient 2. The 
Pfcrt72–76 haplotype was CVMNK before adaptation and 
CVIET after adaptation for both patients by sequencing. 
Resistance was confi rmed by in vitro methods after culture 
adaptation. Both isolates had high chloroquine IC50 (506 
nM and 708 nM, respectively) and high chloroquine IC50 
isolate:Pf3D7 (chloroquine susceptible clone) ratio (20 and 
27, respectively) (Table 2).
Patient 1, a 58-year-old woman, was in Haiti during 
October 2009–January 2010; she returned after the 
earthquake to Canada, where she sought care for malaise, 
fever, diarrhea, and vomiting. She reported no previous 
malaria and no other travel during the previous 2 years. 
For patient 2, a 16-year-old girl, malaria was diagnosed in 
Canada on February 25, 2010, after 3 days of fever. She 
had traveled to Haiti in the past 2 months before malaria 
was diagnosed and did not report any other recent travel.
Conclusions
The number of P. falciparum–infected travelers 
returning from Haiti has increased since January 2010, 
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Table 1. Characteristics of travelers returning from Haiti to 
France, 1988–2010, and Canada, 2007–2010 
Characteristic
Before
earthquake,  
n = 49*
After
earthquake,  
n = 30* 
Median age, y (range) 44 (0.7–69) 36 (2–77)
Sex
 M 32 (68) 19 (63)
 F 15 (32) 11 (37)
Country of residence
 France 49 (100) 27 (90)
 Canada 0 3 (10) 
Plasmodium falciparum
infection
47 (100) 27 (100) 
Chemoprophylaxis
 No 37 (76) 23 (77)
 Yes 1 (2) 2 (7)
 Unknown 11 (22) 5 (17)
Duration of stay
 <2 wk 5 (17) 3 (14)
 2–4 wk 14 (47) 6 (29)
 1–3 mo 7 (23) 7 (33)
 >3 mo 4 (13) 5 (24)
Purpose of travel
 Tourism 4 (12) 3 (13)
 Visit friends and family 20 (59) 10 (44)
 Business 5 (15) 3 (13)
 Military 1 (3) 0
 Residents or expatriates 
 >6 mo
1 (3) 5 (22)
 Other 3 (9) 2 (9)
Severe malaria
 Yes 1 (3) 3 (11)
 No 28 (97) 24 (89)
Median parasitemia 
(range)†
0.47
(0.001–12.000)
0.57
(0.04–14.00)
*Values are no. (%) except as indicated. Numbers may not add to totals 
because of missing information. 
†Percentage of infected erythrocytes per mL blood. 
Figure 1. Surveillance during 23 years for antimalarial drug 
resistance in travelers returning to France and Canada from Haiti 
after the January 10, 2010, earthquake. A) Imported malaria cases 
from Haiti reported in France (1988–2010) and Canada (2007–
2010). B) Total number of Plasmodium falciparum infections, by 
month, 2009 and 2010.
probably because of the higher number of aid workers and 
visitors and increased P. falciparum malaria transmission. 
Data suggest that the earthquake and ensuing hurricane 
and fl oods created the necessary conditions—inadequate 
shelters, population movement, and still water—to increase 
the incidence of malaria and possibly spread the recently 
identifi ed chloroquine-resistant strains of P. falciparum 
(10). In France and Canada, laboratory surveillance 
for malaria found that 2 travelers from Haiti carried 
chloroquine-resistant strains. In vitro culture might have 
selected resistant strains not observed initially by ex vivo 
methods. After carefully interviewing these patients about 
their travels, we found no evidence to cause doubt that they 
had acquired malaria in Haiti. Alternatively, the resistant 
strains could have come to Haiti after the earthquake through 
human activity, as occurred in the cholera outbreak (13). 
The origin of the chloroquine-resistant strains identifi ed in 
Haiti is uncertain. The Pfcrt CVIET haplotype is common 
in Southeast Asia and sub-Saharan Africa and was found in 
the 2006–2007 study in Haiti (10).
Regardless of origin, containing the spread of 
chloroquine-resistant parasites is crucial. Malaria 
elimination is a goal in Haiti, and it has been strengthened 
after recent events, but the effects of malaria and many 
other factors affect the achievability of this goal (14). 
Control measures, possibly mirroring those used to 
contain artemisinin resistance in Southeast Asia, should be 
concentrated in Haiti to prevent resistance spreading to the 
rest of Hispaniola (15). However, lack of consensus on the 
use of molecular and in vitro data for policy change will 
hamper decision making. Neither the chloroquine-resistant 
Pfcrt76T genotype nor the elevated chloroquine IC50 
perfectly predicts treatment failure because of confounding 
factors like acquired immunity.
Our study has several limitations. Returning travelers 
are not a representative sample of the Haitian population, 
and the sample of isolates was limited. The origin of the 
resistant strains is not defi ned. Also, the precise location 
of infection is not reported. Nevertheless, travelers are 
useful sentinels of emerging resistance in areas where 
little information is available, providing surveillance data 
in real time with standardized methods. This nonimmune 
population also facilitates detection of resistant isolates.
Our data highlight the need to implement a therapeutic 
effi cacy surveillance study for assessing in vivo chloroquine 
sensitivity, which is essential for providing information 
for rational control strategies and guiding prophylaxis 
recommendations in Haiti. In addition, physicians treating 
malaria acquired in Haiti should be aware of the possibility 
of chloroquine-resistant infections. Patients with persistent 
fever despite treatment and infected travelers reporting 
adherence to chloroquine prophylaxis should be treated 
with alternate antimalarial drug therapy.
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Figure 2. Departments of Haiti.
Table 2. Molecular genotypes and in vitro susceptibility for 
Plasmodium falciparum isolates from patients returning to France 
and Canada from Haiti 
Characteristics
Before
earthquake,
n = 49
After
earthquake,
n = 30
In vitro analysis n = 24 n = 10
IC50 for chloroquine, nmol/L (mean 
95% CI)
27 (23–31) 35 (12–105)*
No. isolates resistant†
 Yes 0 2
 No 24 8
Molecular marker analysis, no. (%) 
isolates
n = 29 n = 19
 PfCRT K76 29 17 (89.5)
 PfCRT K76+76T 0 2 (10.5)
 PfCRT 76T 0 0
*The 2 resistant isolates are included with an IC50 of 506 nmol/L and 708 
nmol/L. IC50, 50% inhibitory concentration. 
†A threshold of IC50 = 100 nmol/L is applied to determine resistant isolates 
(consensus between the laboratories in France and Canada) and in vitro 
susceptibility (IC50) for the isolates from patients returning from Haiti. 
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